Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 75
States / cities: Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more

Conditions: Pulmonary Hypertension
Interventions: Cardiac Resynchronization Therapy (CRT); Device
Lead sponsor: Dr. Daniel P Morin, MD MPH FHRS; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Application Site Pigmentation Changes
Interventions: latanoprost, bimatoprost, travoprost; Drug
Lead sponsor: Summa Health System; Other
Eligibility: 30 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Arlington Heights, Illinois • Akron, Ohio

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 6 more

Conditions: Chronic Kidney Disease, Hypertension
Interventions: outpatient clinic kidney-protective care; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 70 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: selexipag (Uptravi); Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Aurora, Colorado • Iowa City, Iowa • Seattle, Washington

Conditions: Hypertension
Interventions: Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Albuminuria, Chronic Kidney Diseases, Cardiovascular Diseases, Hypertension
Interventions: Mailed Urinalysis Smartphone Kit; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Disease, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Anastrozole, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Providence, Rhode Island

Conditions: Primary Open-angle Glaucoma
Interventions: Questionnaires; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cataract, Glaucoma, Retinitis Pigmentosa, Macular Degeneration, Strabismus
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions: Not listed
Lead sponsor: Alexander Eaton; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Zona Plus Device, Relaxing Music App; Device · Other
Lead sponsor: Zona Health, Inc; Industry
Eligibility: 22 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Valley Village, California • West Hills, California • Plantation, Florida + 7 more

Conditions: Inflammation, Cancer, Pain, Hypertension
Interventions: Sulindac; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona • Stony Brook, New York

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: ICOS-Texas Biotechnology; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 21 more

Conditions: Hypertension, Diabetes Mellitus
Interventions: Home blood pressure monitor; Behavioral
Lead sponsor: Exempla Saint Joseph Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypertension
Interventions: Sildenafil Oral Suspension, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension
Interventions: AI-Driven Lifestyle Coaching Program; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Liver Cirrhosis, Liver Diseases, Hypertension, Portal
Interventions: EchoTip® Insight™ Portosystemic Pressure Gradient Measurement System (EchoTip® Insight™); Device
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Orange, California • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Hypertension, Pulmonary
Interventions: Assigned pulmonary hypertension medication; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 2,691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

Cardiac Resynchronization Therapy in Pulmonary Hypertension

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Community-Based Screening for Chronic Kidney Disease

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit

Functional and Structural Imaging for Glaucoma

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Anastrozole in Patients With Pulmonary Arterial Hypertension

Impact of Glaucoma and Visual Field Loss on Life Space

Potential Research Participants for Future Studies of Inherited Eye Diseases

Eye Drop Application Monitor, Pilot Study

A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects

NSAID Effects on Clinical and Imaging Breast Biomarkers

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Do Home Monitors Improve Blood Pressure Control?

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

An Artificial Intelligence-Assisted Digital Health Lifestyle Intervention for Adults With Hypertension

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

Topical Insulin for Glaucoma